CLDX


ASCO Updates: Cowen Analysts Weigh In on Exelixis, Inc. (EXEL), Ariad Pharmaceuticals, Inc. (ARIA) and Celldex Therapeutics, Inc. (CLDX)

With more than 30,000 attendees, the American Society of Clinical Oncology (ASCO) annual meeting is the largest cancer conference in the world. As …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Reports First Quarter 2016 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2016 “While the recent setback of the …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Analysts See Recent Data from Celldex Therapeutics, Inc. (CLDX) and Ariad Pharmaceuticals, Inc. (ARIA) Through Rose Colored Glasses

Healthcare analysts expressed their views on drug makers Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Ariad Pharmaceuticals, Inc.

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced new safety and immune response data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort …

Analysts Have Mixed Views on Celgene Corporation (CELG) and Celldex Therapeutics, Inc. (CLDX) Following Recent Announcements

Celgene Corporation (NASDAQ:CELG) announced an ANDA for its drug Abraxane yesterday. Due to the complex circumstances and probable litigation, one analyst predicts a …

Analysts Shine Light On Two Volatile Healthcare Stocks: Celldex Therapeutics, Inc. (CLDX), Invivo Therapeutics Holdings Corp (NVIV)

As two biotech companies continue announce pipeline progressions, for better or worse, analysts weigh in on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Invivo Therapeutics …

Monday Morning’s Insights: Celldex Therapeutics, Inc. (CLDX), Linn Energy LLC (LINE), LinnCo LLC (LNCO)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shareholders are having a rough morning as the company’s shares are collapsing, down 51% in pre-market trading Monday, after the company announced that …

Company Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Concludes RINTEGA Trial

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts